Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909099 | 0.89 | LMNA (0.72) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL3319225 | 0.87 | SMN1; SMN2 (0.65) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL9491289 | 0.86 | LMNA (0.83) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL6290094 | 0.86 | L3MBTL1 (0.76) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL1928397 | 0.86 | L3MBTL1 (1.00) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL10604330 | 0.86 | L3MBTL1 (0.70) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL5862258 | 0.85 | L3MBTL1 (0.73) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL5862900 | 0.85 | L3MBTL1 (0.73) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL31055438 | 0.83 | L3MBTL1 (0.82) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL27611122 | 0.83 | LMNA (0.78) | L3MBTL1NPC1RAB9ALMNATP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640083-A | GPR52 modulator compound | 江苏海洋大学 | 2023-08-25 | — | — | CN | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | disclosed |
| CN-101535307-B | Triazole derivatives as kinase inhibitors | CELLZOME UK LTD | 2013-10-30 | — | — | CN | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| CN-101535307-A | Triazole derivatives as kinase inhibitors | CELLZOME UK LTD (GB) | 2009-09-16 | — | — | CN | disclosed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | L3MBTL1 3597/4885NPC1 3936/4885RAB9A 1897/4885 |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | ITK, PIK3C3, TXK | L3MBTL1 4352/4885NPC1 2979/4885RAB9A 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.